Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence

Abstract EN

Asthma is the commonest chronic disease affecting airways in humans and has an increasing global disease burden.

Inhaled corticosteroids (ICS) are the first-line therapeutic option for asthma, and addition of a long-acting beta 2-agonist (LABA) has been shown to improve asthma control.

A combination of the two agents in a single inhaler is beneficial with regard to ease of administration and patient compliance.

Various ICS-LABA formulations are available across various countries in the world, one among them being formoterol-fluticasone.

Both formoterol and fluticasone have pharmacologic peculiarities which places the combination in a uniquely advantageous position when it comes to asthma therapy.

The present review focuses on some of the, hitherto, less explored aspects of this combination inhaler such as real-world efficacy, impact on budget allocation, results of switch-over therapy, and potential to improve adherence to asthma treatment.

It also provides practical recommendations on positioning it in real-world asthma management.